Global Urinalysis Market to Generate $5,719.3 Million by 2031, Owing to the Growing Prevalence of Urinary Tract Infections (UTI)

Urinalysis is a medical test usually done to check for ailments like kidney malfunctioning, diabetes, urinary tract infections, etc. Urinalysis generally involves testing urine for several parameters including its color, odor, pH level, appearance, etc. Also, the patient’s urine is checked if there are any bacteria, fungi, blood traces, protein traces, cells and crystals, etc., are present in it. Urinalysis is one of the most common tests done before any medical treatment or medication is prescribed by the doctor.

Forecast Analysis of the Urinalysis Market

In recent years, there has been an increase in the prevalence of urinary tract infections across the globe which is expected to be the primary growth driver of the global urinalysis market in the forecast years. Along with this, growing demand for point-of-care testing is expected to push the market further. Also, rising global patient population and improving healthcare infrastructure is predicted to offer numerous investment and growth opportunities to the market in the analysis timeframe. However, lack of standardization in tests may restrain the growth of the urinalysis market in the forecast period.

Geographically, the urinalysis market in the North America region is expected to be the most dominant by 2031. The growing geriatric population across the region is anticipated to become the main growth driver of the market in the forecast period.

According to the report published by Research Dive, the global urinalysis market is expected to gather a revenue of $5,719.3 million by 2031 and grow at 6.4% CAGR in the 2022-2031 timeframe. Some prominent market players include Abbott, ARKRAY Inc, Quidel Corporation, Sysmex Corporation, ARKRAY Inc, Bio-Rad Laboratories, Inc., Siemens Healthcare Gmbh, F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd, ACON Laboratories, Inc., and many others.

Covid-19 Impact on the Urinalysis Market

The outbreak of the Covid-19 pandemic has had a massive negative effect on almost all industries and businesses across the world. The urinalysis market, however, was an exception. As the pandemic spread across the world, the demand for urinalysis increased for ascertaining the ailment and prescribing appropriate treatment for the patient. This increased demand helped the market to post growth numbers despite the pandemic.

Significant Market Developments

The significant companies operating in the industry are adopting numerous growth strategies & business tactics such as partnerships, collaborations, mergers & acquisitions, and launches to maintain a robust position in the overall market, thus helping the urinalysis market to flourish. For instance:

• In June 2020, Healthy.io, an Israeli urinalysis and wound-care company, announced the acquisition of Inui Health, a medical diagnostics firm. This acquisition is predicted to boost the market share of the acquiring company i.e., Healthy.io in the near future.
   
• In September 2021, Beckman Coulter, a biomedical products manufacturer, announced the launch of its innovative urinalysis solution, viz., DxU Iris Workcell. DxU Iris Workcell, a fully automated system, has been shown to reduce the subjectivity and variability in urinalysis tests. The product launch is expected to help the company to increase its market share in the coming period and establish itself as a leader in the industry.
   
• In September 2022, Sysmex Corporation, a medical company, announced the launch of UF-1500 Fully Automated Urine Particle Analyzer (UF-1500). This product is designed for urine sediment testing, an important component of urinalysis, and the product launch is predicted to help the company to cater to the demands of the medical sector in a holistic manner.